Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Merola

Showing results (301-310 of 351) with videos related to

Pageof 36
Sort By:
The Journal of Clinical Investigation|January 16, 2019
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosusRichard Furie, Victoria P Werth, Joseph F Merola, et al.
JAMA Dermatology|June 26, 2020
Creation and Validation of Classification Criteria for Discoid Lupus ErythematosusScott A Elman, Cara Joyce, Kara Braudis, et al.
Rheumatology and Therapy|August 31, 2024
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Rheumatology and Therapy|May 10, 2025
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Rheumatology Advances in Practice|November 15, 2021
Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort studyMarie Skougaard, Tanja S Jørgensen, Mia J Jensen, et al.
Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 28, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical TrialJoseph F Merola, Philip Mease, Alan Kivitz, et al.
Arthritis Research & Therapy|February 12, 2024
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsAtul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.
RMD Open|July 15, 2026
Psoriatic arthritis and obesity: a review of clinical burden and considerations for comprehensive careNorman Madsen, Laura C Coates, Joseph F Merola, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 20, 2024
Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting ProceedingsCarly Grant, Lourdes Perez-Chada, Rebecca H Haberman, et al.
Pageof 36

Showing results (301-310 of 351) with videos related to

Sort By:
Pageof 36
The Journal of Clinical Investigation|January 16, 2019
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosusRichard Furie, Victoria P Werth, Joseph F Merola, et al.
JAMA Dermatology|June 26, 2020
Creation and Validation of Classification Criteria for Discoid Lupus ErythematosusScott A Elman, Cara Joyce, Kara Braudis, et al.
Rheumatology and Therapy|August 31, 2024
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Rheumatology and Therapy|May 10, 2025
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Rheumatology Advances in Practice|November 15, 2021
Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort studyMarie Skougaard, Tanja S Jørgensen, Mia J Jensen, et al.
Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 28, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical TrialJoseph F Merola, Philip Mease, Alan Kivitz, et al.
Arthritis Research & Therapy|February 12, 2024
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsAtul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.
RMD Open|July 15, 2026
Psoriatic arthritis and obesity: a review of clinical burden and considerations for comprehensive careNorman Madsen, Laura C Coates, Joseph F Merola, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 20, 2024
Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting ProceedingsCarly Grant, Lourdes Perez-Chada, Rebecca H Haberman, et al.
Pageof 36